Haemonetics elects Martin Madaus to board, to join Audit and Governance committees

Haemonetics elected Martin Madaus as a director, effective July 24, 2026, with expected appointments to the Audit Committee and the Governance and Compliance Committee.Original SEC Filing: HAEMONETICS CORP [ HAE ] - 8-K - Jul. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Cons…

Haemonetics elected Martin Madaus as a director, effective July 24, 2026, with expected appointments to the Audit Committee and the Governance and Compliance Committee.

IndividualMartin Madaus

RoleDirector; expected member of Audit Committee and Governance and Compliance Committee

Type of ChangeAppointed / Elected

Effective DateJuly 24, 2026

ReasonNot disclosed

Replacement InfoNot disclosed

Background DetailsSenior Operating Executive at The Carlyle Group since 2019; advises on healthcare investments and portfolio company performance

Board/Committee Role ChangesExpected appointment to Audit Committee and Governance and Compliance Committee

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.